baricitinib

Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis

Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis

Yahoo

Lilly arthritis drug shows durability in study

Lilly arthritis drug shows durability in study

Reuters

Eli Lilly: New Drug Shows Strong Potential

Eli Lilly: New Drug Shows Strong Potential

Seeking Alpha

Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor

Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor

PharmPro

Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis

Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis

Yahoo